750,000 Shares in Drugs Made In America Acquisition II Corp. $DMII Bought by Context Capital Management LLC

Context Capital Management LLC acquired a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 750,000 shares of the company’s stock, valued at approximately $7,425,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Deltec Asset Management LLC acquired a new position in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $495,000. Wolverine Asset Management LLC bought a new position in Drugs Made In America Acquisition II in the fourth quarter worth about $10,521,000. ABC Arbitrage SA bought a new position in Drugs Made In America Acquisition II in the fourth quarter worth about $396,000. Wealthspring Capital LLC acquired a new position in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $4,049,000. Finally, HighTower Advisors LLC bought a new position in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $7,817,000.

Drugs Made In America Acquisition II Trading Up 0.0%

DMII opened at $10.09 on Friday. The company’s 50 day simple moving average is $10.03. Drugs Made In America Acquisition II Corp. has a twelve month low of $9.86 and a twelve month high of $10.09.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DMII shares. Weiss Ratings reiterated a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research report on Friday, May 29th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.